Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary breast cancer families.

Fachal L, Santamariña M, Blanco A, Carracedo A, Vega A.

Clin Transl Oncol. 2013 Feb;15(2):164-5. doi: 10.1007/s12094-012-0967-z. Epub 2012 Nov 13. No abstract available.

PMID:
23150219
2.

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P.

Cancer Res. 2003 Dec 1;63(23):8153-7.

3.

Absence of CHEK2 mutations in Spanish families with hereditary breast cancer.

Bellosillo B, Tusquets I, Longarón R, Pérez-Lezaun A, Bellet M, Fabregat X, Serrano S, Solé F.

Cancer Genet Cytogenet. 2005 Aug;161(1):93-5. No abstract available.

PMID:
16080966
4.

The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.

Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG.

Breast Cancer Res Treat. 2008 Dec;112(3):569-73. doi: 10.1007/s10549-007-9878-z. Epub 2008 Jan 3.

PMID:
18175216
5.

Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.

de Bock GH, Mourits MJ, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG.

Int J Gynecol Cancer. 2006;16 Suppl 2:552-5.

PMID:
17010071
6.

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.

Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG.

J Clin Oncol. 2008 Feb 1;26(4):542-8. doi: 10.1200/JCO.2007.12.5922. Epub 2008 Jan 2. Review.

PMID:
18172190
7.

Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals.

Jekimovs CR, Chen X, Arnold J, Gatei M, Richard DJ, Spurdle AB, Khanna KK, Chenevix-Trench G; kConFab Investigators..

Br J Cancer. 2005 Feb 28;92(4):784-90.

8.

[CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China].

Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Aug;23(4):443-5. Chinese.

PMID:
16883537
9.

Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations?

Gutiérrez-Enríquez S, Balmaña J, Baiget M, Díez O.

Breast Cancer Res Treat. 2008 Feb;107(3):455-7. Epub 2007 Apr 26. No abstract available.

PMID:
17458694
10.

German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.

Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, Pierl CB, Brüning T, Ko Y, Benner A, Wichmann HE, Brauch H, Hamann U; GENICA Network..

Eur J Cancer. 2005 Dec;41(18):2896-903. Epub 2005 Oct 18.

PMID:
16239104
11.

Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.

Adank MA, Verhoef S, Oldenburg RA, Schmidt MK, Hooning MJ, Martens JW, Broeks A, Rookus M, Waisfisz Q, Witte BI, Jonker MA, Meijers-Heijboer H.

Eur J Cancer. 2013 May;49(8):1993-9. doi: 10.1016/j.ejca.2013.01.009. Epub 2013 Feb 14.

PMID:
23415889
12.

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.

Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, Palli D, Ottini L.

Breast Cancer Res Treat. 2008 Jul;110(1):161-7. Epub 2007 Jul 28.

PMID:
17661168
13.

Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.

Iniesta MD, Gorin MA, Chien LC, Thomas SM, Milliron KJ, Douglas JA, Merajver SD.

Cancer Genet Cytogenet. 2010 Oct 15;202(2):136-40. doi: 10.1016/j.cancergencyto.2010.07.124.

PMID:
20875877
14.

Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.

Konecny M, Milly M, Zavodna K, Weismanova E, Gregorova J, Mlkva I, Ilencikova D, Kausitz J, Bartosova Z.

Breast Cancer Res Treat. 2011 Feb;126(1):119-30. doi: 10.1007/s10549-010-1325-x. Epub 2011 Jan 4.

PMID:
21203900
15.

CHEK2 1100delC and male breast cancer in the Netherlands.

Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M.

Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31.

PMID:
18759107
16.

Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.

Manoukian S, Peissel B, Frigerio S, Lecis D, Bartkova J, Roversi G, Radice P, Bartek J, Delia D.

Breast Cancer Res Treat. 2011 Nov;130(1):207-15. doi: 10.1007/s10549-011-1548-5. Epub 2011 May 12.

PMID:
21562711
17.

CHEK2:1100delC and female breast cancer in the United States.

Mateus Pereira LH, Sigurdson AJ, Doody MM, Pineda MA, Alexander BH, Greene MH, Struewing JP.

Int J Cancer. 2004 Nov 10;112(3):541-3. No abstract available.

18.

[The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].

Pohlreich P, Kleibl Z, Kleiblová P, Janatová M, Soukupová J, Macháčková E, Házová J, Vašíčková P, Sťahlová Hrabincová E, Navrátilová M, Svoboda M, Foretová L.

Klin Onkol. 2012;25 Suppl:S59-66. Review. Czech.

PMID:
22920209
19.

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR; CHEK2-Breast Cancer Consortium..

Nat Genet. 2002 May;31(1):55-9. Epub 2002 Apr 22.

PMID:
11967536
20.

CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.

Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ, Hogervorst FB, van den Ouweland AM, Gille JJ, Schmidt MK, van der Vaart AW, Meijers-Heijboer H, Waisfisz Q.

J Med Genet. 2011 Dec;48(12):860-3. doi: 10.1136/jmedgenet-2011-100380. Epub 2011 Nov 5.

PMID:
22058428

Supplemental Content

Support Center